BPC-157 vs TB-500: What Is the Difference?
BPC-157 is a fifteen-amino-acid peptide studied in angiogenesis and cell-signalling research, while TB-500 is a seven-residue peptide that binds actin, the cytoskeletal protein cells assemble and disassemble. TB-500 is cut from thymosin beta-4 and is a short fragment of it, not the whole 43-residue protein, which is why the two names are not interchangeable. Supplied for in vitro research purposes only.
5 minute read
What Is the Difference Between BPC-157 and TB-500?
Both are short synthetic peptides studied in cell-signalling research. They are unrelated sequences with different molecular targets.
BPC-157 is a 15-amino-acid sequence taken from a larger protein found in gastric fluid. It is studied in vascular and connective-tissue research, and ARP supplies it lyophilised.
TB-500 is a seven-amino-acid fragment studied in cell-motility research. It binds G-actin, the protein subunit the cytoskeleton is assembled from.
A rough way to hold the difference: different lengths, different parent proteins, different molecular targets.
| BPC-157 | TB-500 | |
|---|---|---|
| Size | 15 amino acids | 7 amino acids |
| Where it comes from | A short section of a larger protein found in stomach fluid | A short section of a protein called thymosin beta-4 |
| Mainly studied for | Vascular and connective-tissue research | Cell-motility research |
What Is BPC-157 Studied For?
Most of the published work sits in vascular research. BPC-157 is a pentadecapeptide — fifteen amino acids — and it is stable enough in aqueous solution to be handled easily on the bench.
It is characterised across a wide range of in vitro and preclinical models, which is why the same fifteen-residue sequence turns up in a number of otherwise unrelated research fields.
What stands out is how thoroughly the sequence itself has been characterised, and how much of that work is molecular rather than clinical. The BPC-157 listing carries the full sequence and the batch certificate.
What Is TB-500 Studied For?
Cell motility. The cytoskeleton is assembled from a protein called actin, and TB-500 binds the free monomer form of it. That binding interaction is what places the fragment in cell-motility research literature.
It also appears in vascular and connective-tissue research literature alongside its parent protein, thymosin beta-4. The TB-500 listing states which material is supplied.
Is TB-500 the Same as Thymosin Beta-4?
No, and this is the single most useful thing to know before reading anything else about it.
Thymosin beta-4 is the full protein. TB-500 is a small piece cut out of it — seven amino acids out of forty-three.
That matters because the full protein does not do the same job all the way along its length. Different sections do different things:
- One section is the actin-binding domain. TB-500 is that section.
- Other regions, elsewhere in the sequence, carry different binding properties entirely. TB-500 does not contain them.
So a study on the full 43-amino-acid protein may be a study about a part of the protein that TB-500 does not have. The two are not interchangeable, and the difference is specific rather than vague.
Separately or as a Blend?
The two are often sold together precisely because they do not overlap. They are unrelated sequences with different molecular targets, so research using both is common.
The BPC-157 + TB-500 blend puts both into a single vial. That fixes the ratio between them and leaves one vial to prepare instead of two. Buying the two listings separately keeps them independent, which is what you want if the work needs one without the other. Peptide types, categories and blends explains the trade-off in more detail.
BPC-157 on its own is HPLC-tested, and the blend is independently lab-tested for identity and amount; both certificates are published in the CoA library. Each listing shows its own current stock.
Common Questions
Neither is a better version of the other. They are unrelated sequences with different molecular targets, so which one suits a piece of research depends entirely on what that research is measuring. No supplier can answer that question for you.
Thymosin beta-4 is a protein of 43 amino acids. TB-500 is a seven-amino-acid piece of it. The piece it contains is the actin-binding domain. Other binding regions of the protein sit elsewhere in the sequence and are not included. So results reported for the full protein may depend on a section the fragment does not have.
BPC-157 is fifteen amino acids long. TB-500 is seven. Both are short enough to be made synthetically and checked by weight, which is what lets a certificate confirm the vial holds what the label says.
Australian Research Peptides supplies the two together as a single pre-combined vial from within Australia, and each of them separately. The blend listing shows its current stock.
All three forms discussed above are listed by Australian Research Peptides — BPC-157 and TB-500 as separate 10 mg vials, and the pre-combined blend in one — each independently lab-tested by batch and posted from Sydney. BPC-157 and the blend are in stock today; TB-500 is not.
Read this article as plain text — BPC-157 vs TB-500: What Is the Difference?, in Markdown — the full text in Markdown, without the page around it, for assistants, screen readers and offline reading.